Third, the interference of chronic somatic disorders such as diabetes, cardiovascular diseases, endocrinological problems, and their specific pharmacological treatment might have affected plasma neuropeptide levels, although the present cohort have not contained such information. This evidence concerns the gene NPS and diabetes mellitus.